Lennart Minthon

Physiology · 2001–2012

A researcher in the Science corpus: 6 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Physiology — 38 citations into it; #1,411 of 2,276 by trust here, #490 by citations
• Psychiatry and Mental health — 32 citations into it; #860 of 1,338 by trust here, #216 by citations

Whom Lennart Minthon trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Kaj Blennow
2. Harald Hampel

Who trusts Lennart Minthon overall

1. Kaj Blennow
2. Katherine R. Gray

Papers from Lennart Minthon's perspective

Ordered by how strongly the researchers Lennart Minthon trusts endorse each paper. Same corpus, a different order for every researcher.

1. Current concepts in mild cognitive impairment. (Archives of Neurology)
2. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade (Lancet Neurology)
3. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (Nature reviews. Drug discovery)
4. Mild cognitive impairment as a diagnostic entity (Journal of Internal Medicine)
5. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment (Journal of Internal Medicine)
6. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (Annals of Neurology)
7. Practical statistics for medical research
8. Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases (Nature Cell Biology)
9. Research criteria for subcortical vascular dementia in clinical trials. (Journal of neural transmission. Supplementum)
10. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. (Lancet Neurology)

Their papers

• Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins (2007) — 1,096 citations
• Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. (2012) — 656 citations
• 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial (2010) — 666 citations
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) — 1,205 citations
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. (2006) — 1,711 citations
• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. (2001) — 609 citations